280 Park Ave,32nd Floor
NEW YORK , NY, 10017
NEW YORK , NY, 10017
Summary
The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.
The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
Next, the research team invests significantly in components of the Unde More
Webiste
Directors
Jun 14, 2023- Matthew Stroyman
- Patrick P. Campo
- Jonathan Krane
- John Ferguson
Chief Compliance Officer
- Michael Quain
Price
- $ 13.46 ( -9.85 )
-
Apr 07, 2025Last Close
- Net Assets
-
$60.6M
Feb 28, 2024
- 52-Week High/Low
- $20.3 - $13
- Expense Ratio
- -
Performance
YTD
0%
3 Year
-41.63%
5 Year
-46.16%
Best
40.43%
2003
Worst
-69.56%
2000
Company Name |
Holding |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd | 9.65 % |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 6.66 % |
| Beigene Ltd | 4.87 % |
| CSPC PHARMACEUTICAL GROUP LIMITED | 4.41 % |
| WUXI BIOLOGICS (CAYMAN) INC. | 3.68 % |
| INNOVENT BIOLOGICS, INC. | 3.67 % |
| ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 3.16 % |
| WuXi AppTec Co., Ltd. | 2.69 % |
| Aier Eye Hospital Group Co., Ltd. | 2.6 % |
| YUNNAN BAIYAO GROUP CO., LTD | 2.53 % |
| More | 2.53 % |
NAV
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KURE | 0% | -18.9% | -18.2% | -25.5% | -2.6% | 27.3% | 34.2% | 0% | 11.8% | 6.8% | |
| S&P 500 | -13.7% | 23.3% | 24.2% | -19.4% | 27.3% | 16.2% | 28.9% | -6.2% | 19.4% | 9.5% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| q1 | 0% | -16.9% | -4.1% | -18.9% | 282% | 2.8% | 28.4% | 0% | 0% | 0% | ||||
| q2 | 0% | -5.9% | -12.2% | 0.4% | -6% | 34% | -9.6% | 0% | 0% | 0% | ||||
| q3 | 0% | 0% | -1.5% | -24.2% | -11.2% | 5.1% | 1.7% | -15.3% | 0% | 0% | ||||
| q4 | 0% | 0% | -0.6% | 20.7% | -4% | -12% | 10% | -22.8% | 0% | 0% |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2024 | -19% | 10% | -6.7% | 1.1% | -3.4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |